( S ) Few studies of medical therapies for endometriosis report outcomes that are relevant to patients , and many women gain only limited or intermittent benefit from treatment
OBJECTIVE To assess patient response rates to medical therapies used to treat endometriosis-associated pain .
Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis.
OBJECTIVE To analyze the secondary efficacy and safety outcomes from a recent trial comparing dienogest ( DNG ) with leuprolide acetate ( LA ) in women with endometriosis . METHODS A 24-week , open-label , r and omized , multicenter study of DNG versus LA  in women with endometriosis-related pain was assessed for outcomes such as responder rates ( using predefined thresholds of pain relief ) , changes in single symptoms/signs and sum scores from the Biberoglu and Behrman ( B&B ) scale , clinical laboratory parameters , and measures of quality of life . RESULTS Dienogest was non-inferior to LA for treatment response using all predefined thresholds of pain relief and provided equivalent improvements in B&B symptoms and signs . No clinical ly relevant changes in laboratory parameters were observed during DNG treatment , whereas estrogen levels decreased in the LA group . Compared with LA , DNG was associated with pronounced improvements in specific quality -of-life measures . CONCLUSION The analyses provide supportive evidence that the efficacy of DNG is equivalent to that of LA for treating endometriosis symptoms , with specific quality -of-life benefits and a favorable safety profile
( S ) Few studies of medical therapies for endometriosis report outcomes that are relevant to patients , and many women gain only limited or intermittent benefit from treatment
OBJECTIVE To assess patient response rates to medical therapies used to treat endometriosis-associated pain .